ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0481 • ACR Convergence 2024

    Differential Effect of Comorbidities on the Clinical Evolution of Early Arthritis by Sex

    Marina Dueñas1, Juan Carlos Sáez1, María Paula Álvarez2, Patricia Quiroga1, Maryia Nikitsina3, Rosario García-Vicuña2, Ana Ortiz4, Isidoro González-Álvaro3 and Irene Llorente-Cubas4, 1Servicio de Reumatología Hospital La Princesa, Madrid, Madrid, Spain, 2Hospital Universitario de La Princesa, Madrid, Madrid, Spain, 3University Hospital La Princesa, Madrid, Madrid, Spain, 4Hospital Universitario de La Princesa, Madrid, Spain

    Background/Purpose: The prevalence of comorbidities is increased in patients with rheumatoid arthritis (RA) compared to the general population1, but their impact in the earlier stages…
  • Abstract Number: 0499 • ACR Convergence 2024

    PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment

    Wanki Ho1, Huaqun Zhu1, Hua Ye1, Dongdong Fu2 and Xi Xu1, 1Peking University People's Hospital, Beijing, China, 2Xinxiang Central Hospital, Xinxiang, Henan, China (People's Republic)

    Background/Purpose: PD-1hiCXCR5-CD4+T peripheral helper cells (Tph) are newly identified pathogenic CD4+T helper cells and participate in rheumatoid arthritis (RA) pathogenesis. However, the clinical significance of…
  • Abstract Number: 0515 • ACR Convergence 2024

    Scavenging Isolevuglandins with 2-HOBA Decreases In Vitro Neutrophil Extracellular Traps in Cells from Patients with Rheumatoid Arthritis

    Olivia Posey, Anastasiia Phothisane, Phicharmon Kulapatana and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Neutrophils contribute to the innate immune response of killing pathogens through the formation of neutrophil extracellular traps (NETs), which is also called NETosis. NETosis…
  • Abstract Number: 0533 • ACR Convergence 2024

    Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized Test Treatment Trial

    Maike Wientjes1, Sadaf Atiqi2, Gertjan Wolbink3, Michael Nurmohamed4, Maarten Boers5, Femke Hooijberg2, Theo Rispens6, Annick De Vries6, Floris Loeff6, Ronald Van Vollenhoven7, Sofia Ramiro8, Noortje van Herwaarden9, Bart van den Bemt10 and Alfons den Broeder1, 1Sint Maartenskliniek, Ubbergen, Netherlands, 2Reade, Amsterdam, Netherlands, 3Reade and Sanquin Diagnostic Services, Amsterdam, Netherlands, 4Reade and Amsterdam UMC, Kortenhoef, Netherlands, 5Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, 6Sanquin Diagnostic Services, Amsterdam, Netherlands, 7Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 8Leiden University Medical Center, Bunde, Netherlands, 9Sint Maartenskliniek, Nijmegen, Netherlands, 10Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands

    Background/Purpose: Adalimumab is an effective and safe treatment for RA, however a substantial proportion of RA patients discontinue its use due to inefficacy. Upon failure,…
  • Abstract Number: 0804 • ACR Convergence 2024

    Serologic and Clinical Predictors of Progressive Pulmonary Fibrosis in Rheumatoid Arthritis-associated Interstitial Lung Disease Progression: A Prospective Longitudinal Cohort

    Sung Hae Chang1, Misti Paudel2, Gregory McDermott3, Qianru Zhang4, You-Jung Ha5, Jeong Seok Lee6, Min Uk Kim7, Chan Ho Park8, Ji-Won Kim9, Jang Woo Ha10, Sang Wan Chung11, Sung Won Lee12, Eun Ha Kang5, Yeon-Ah Lee13, Jung-Yoon Choe14, Yong-Beom Park15, Eun Young Lee16 and Jeffrey Sparks17, and the KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) group, 1Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, 2Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 3Brigham and Women's Hospital, Brookline, MA, 4Harvard medical school, Cambridge, MA, 5Seoul National University Bundang Hospital, Seongnam, South Korea, 6Korea Advanced Institute of Science and Technology, KAIST,, Daejeon, Republic of Korea, 7SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, 8Soonchunhyang University College of Medicine,, Cheonan-si, Republic of Korea, 9Daegu Catholic University School of Medicine, Nam-gu, Daegu, South Korea, 10Yonsei university college of medicine, Seodaemun-gu, Seoul, South Korea, 11Kyung Hee University Hospital, Seoul, Republic of Korea, 12Soonchunhyang University Cheonan Hospital, Seoul, South Korea, 13Kyung Hee University Hospital, Seoul, South Korea, 14Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, 15Yonsei University College of Medicine, Seoul, Republic of Korea, 163Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 17Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: Predictors of progressive pulmonary fibrosis (PPF) in patients with rheumatoid arthritis-associated interstitial lung disease (ILD) are unclear but may be due to inflammation or…
  • Abstract Number: 0903 • ACR Convergence 2024

    Distinct Impacts of Mosaic Loss of Chromosome Y and Genetic Risk on the Age of Onset in Patients with Rheumatoid Arthritis

    Shunsuke Uchiyama1, Yuki Ishikawa2, Katsunori Ikari3, Suguru Honda4, Yoichiro Kamatani5, Takahisa Gono6, Masataka Kuwana7 and Chikashi Terao8, 1Nippon Medical school/ RIKEN, Tokyo, Japan, 2RIKEN, Yokohama, Japan, 3Tokyo Women's Medical University, Shinjuku, Japan, 4Tokyo Women's Medical University, Tokyo, Japan, 5Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan, 6Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 7Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 8RIKEN, Tokyo, Japan

    Background/Purpose: The age of onset of rheumatoid arthritis (RA) is becoming older worldwide. Since patients with late-onset RA (LORA) have unique clinical characteristics, including acute…
  • Abstract Number: 0950 • ACR Convergence 2024

    Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde (MAA) Modified Vimentin Induces Fibrotic Lung Changes

    Wenxian Zhou1, Michael Duryee2, Nozima Aripova2, Jill Poole2, Carlos Hunter2, Amy Nelson2, Bryant England2, Ted Mikuls2 and Geoffrey Thiele2, 1University of Nebraska Medical Center, Bellevue, NE, 2University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is the most overrepresented cause of death among RA patients, yet the mechanisms underlying lung fibrosis remain…
  • Abstract Number: 1022 • ACR Convergence 2024

    Social Determinants of Health in Osteoporosis Treatment Patterns Among Adults with Rheumatoid Arthritis and Major Osteoporotic Fracture in the All of Us Research Program: A Cross-Sectional Study

    Marshall Weber1, Brinda Basida2, Colton Hoffer2 and Rachel Elam3, 1Augusta University, Augusta, GA, 2Augusta University / VA Augusta Health System, Augusta, GA, 3Augusta University, Evans, GA

    Background/Purpose: Despite widely available bone health pharmacologic therapies, there is a significant osteoporosis treatment gap in individuals with rheumatoid arthritis (RA). The aim of this…
  • Abstract Number: 1098 • ACR Convergence 2024

    Prognostic Value of Hyperuricemia in Developing Cardiovascular Events in Patients with Chronic Inflammatory Arthritis: A 10-Year Prospective Study

    Antonio Avilés1, Zulema Plaza2, Fernando Sánchez-Alonso3, Santos Castañeda4, Benjamin fernandez-Gutierrez5, César Díaz6, Pilar Font7, Olga Martinez8, Emilio Giner9, José Miguel Senabre10, Amalia Rueda11, Ana Perez12, Gines Sanchez13, Carlos Gonzalez14, Javier García15, Javier Llorca16, Miguel Angel Gonzalez-Gay17 and Mariano Andres18, and CARMA project, reserch group., 1Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, 2Fundacion Española de Reumatología, Madrid, Spain, 3Sociedad Española de Reumatología, Madrid, Spain, 4Hospital Universitario de la Princesa, Madrid, Spain, 5HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, 6Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 7IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 8Hospital Universitario de Salamanca, Zamora, Spain, 9Hospital Royo Villanova, Teruel, Spain, 10Hospital Marina Baixa Alicante, Alicante, Spain, 11Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, 12Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, 13Hospital General de Albacete, Albacete, Spain, 14Hospital Universitario Lucus Augusti; Biodiscovery HULA-USC Group, Instituto de Investigación Sanitaria de Santiago de Compostela IDIS., Lugo, Spain, 15Hospital Universitario 12 de Octubre, Madrid, Spain, 16CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, 17University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 18Hospital General Universitario de Alicante, Alicante, Spain

    Background/Purpose: The role of concurrent hyperuricemia as a cardiovascular risk factor in patients with chronic inflammatory arthritis (CIA) has yet to be studied. We aim…
  • Abstract Number: 1331 • ACR Convergence 2024

    Does Refractory Rheumatoid Arthritis Status Matter in Modeling Patient Global Assessment Trajectories over 20 Years in a Large US Registry?

    Sofia Pedro1, Kristin Wipfler2, Urbano Sbarigia3, Federico Zazzetti4, Anna Sheahan5, Patti Katz6 and Kaleb Michaud7, 1Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 2FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 3Johnson & Johnson Innovative Medicine, Brussels, Belgium, 4Johnson & Johnson Innovative Medicine, Horsham, PA, PA, 5Janssen, Chapel Hill, NC, 6UCSF, San Rafael, CA, 7University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Refractory rheumatoid arthritis (reRA) is characterized by an inadequate response to multiple DMARDs. Many factors including environment, comorbidities, sociodemographics, and the treatment itself influence poor…
  • Abstract Number: 1347 • ACR Convergence 2024

    Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice

    Manon Lesturgie-Talarek1, Fabien Picard2, sabrina hamroun3, Malika Saadi2, Camille Macher4, Aude Deloumeau3, Karim Wahbi2, jacques Blacher4, Yannick Allanore5 and Jérôme Avouac6, 1Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, 2Cardiology Department - Cochin Hospital, Paris, France, 3Rheumatology Department - Cochin Hospital, Paris, France, 4Cardiology Department, Hôtel Dieu Hospital, Paris, France, 5Université Paris Cité, Paris, France, 6Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France

    Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular (CV) mortality, linked to systemic inflammation and the presence of associated CV risk factors.…
  • Abstract Number: 1363 • ACR Convergence 2024

    Prevalence and Predictors of Orthopaedic Surgery in Rheumatoid Arthritis After 12-Years’ Follow-Up (ESPOIR Cohort)

    Michael Wang1, Baptiste Quere1, Paul Thomas1, Alice TISON2, Dewi Guellec1, Cecile Gaujoux-Vialat3, Jean Francis Maillefert4, Sandrine Jousse-Joulin5, Valerie Devauchelle6, Hoel Letissier1 and Alain SARAUX7, 1Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, 2CHU de la Cavale Blanche, Brest, France, Brest, France, 3CH Nimes, Nimes, France, 4CH Dijon, Dijon, France, 5cavale blanche hospital, brest, France, 6UBO, Brest, France, 7CHU Brest, Brest, France

    Background/Purpose: In the 1990s, surgery was a frequent and early step in the management of rheumatoid arthritis. Since treat to target strategy and the advent…
  • Abstract Number: 1379 • ACR Convergence 2024

    Association Between Body Mass Index and the Persistence of Non-TNF-Targeted Biologics in Patients with Rheumatoid Arthritis

    Dong-Jin Park1, Hyemin Jeong2, Sung-Eun Choi3, Ji-Hyoun Kang2 and Shin-Seok Lee4, 1Chonnam National University Medical School and Hospital, Gwangju, South Korea, 2Chonnam National University Hospital, Gwangju, South Korea, 3Chonnam National University Medical School & Hospital, Gwangju, South Korea, 4Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea

    Background/Purpose: Recent studies have shown the impact of obesity on achieving low disease activity (LDA) or remission in rheumatoid arthritis (RA) patients treated with TNF…
  • Abstract Number: 1396 • ACR Convergence 2024

    Low CD47 Expression on B Cells, Induces High B Cell Phagocytosis by Macrophages and Is a Predictive Biomarker of Anti-rituximab Antibodies and Lower Response in Rheumatoid Arthritis

    Samuel Bitoun1, Bineta Ly2, Audrey Paoletti2, Catherine Menier Menier3, Marc Pallardy4, Bernard Maillere5 and Xavier Mariette6, and ABIRISK consortium, 1Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, 2Rheumatology departement, Université Paris Saclay, Inserm UMR 1184,Hopital Bicêtre, APHP, FHU CARE, Le Kremlin Bicêtre, France, 31 CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, 4Université Paris-Saclay, INSERM, Inflammation Microbiome Immunosurveillance, Orsay, France, 5CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Université de Paris-Saclay, Gif sur Yvette, France, 6Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Rituximab (RTX) provides long lasting efficacy in the control of rheumatoid arthritis. Among factors associated with RTX failure are the occurrence of anti-drug antibodies…
  • Abstract Number: 1664 • ACR Convergence 2024

    Identification of Spatial Determinants of Treatment Response in Rheumatoid Arthritis Synovia

    ilya Korsunsky1, Roopa Madhu2, Kevin Wei3, Kartik Bhamidipati1, Miles Tran1, Sonia Presti1, Anna Helena Jonsson4, Ellen Gravallese5, Michael Brenner6, Soumya Raychaudhuri1, Jennifer Seifert7, Costantino Pitzalis8, Fan Zhang9, Larry Moreland10, V. Michael Holers10, Michael Clayman11, Myles Lewis12, Ce Gao1, Michael J Zuscik13 and Accelerating Medicines Partnership Autoimmune and Immune-Mediated Disease14, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Brookline, MA, 3Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 4University of Colorado School of Medicine, Aurora, CO, 5Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, 6Brigham and Women's Hospital, Harvard Medical School, Newton, MA, 7University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, 8QMUL, Bromley Kent, United Kingdom, 9University of Colorado, Aurora, CO, 10University of Colorado, Denver, CO, 11University of Colorado School of Medicine, Burlington, MA, 12Queen Mary University of London, London, United Kingdom, 13Department of Orthopedic Surgery, University of Colorado School of Medicine, Aurora, CO, 14Multiple Institutions, Oklahoma City

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by immune infiltration of the synovial tissue, resulting in joint damage. In RA, synovia exhibit distinct…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology